Placebo omalizumab

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

AllergyAsthmaHay FeverHypersensitivityRhinitis

Phase 2

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

CompletedNCT00078195

National Institute of Allergy and Infectious Diseases (NIAID)Allergy, Hay Fever, Hypersensitivity +1

Start: 2003-04-30End: 2005-05-31Target: 168Updated: 2016-10-18

Phase 4

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

CompletedNCT01430403

National Institute of Allergy and Infectious Diseases (NIAID)Asthma

Start: 2011-09-30End: 2014-03-31Updated: 2017-05-30

Related Papers

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma

American Journal of Respiratory and Critical Care Medicine2017-06-13247 citations

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

2015-10-27362 citations